Clinical Trials Browser

Active not recruiting × Hodgkin Disease × Carboplatin × Clear all

NCT03016871 2025-10-20

Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL

Phase 2 Active not recruiting

78 enrolled 15 charts

Hodgkin Disease